Ono Pharmaceutical Co (Ono Pharmaceutical Co) Cash-to-Debt

: 15.79 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ono Pharmaceutical Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 15.79.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ono Pharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ono Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

OPHLY' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.11 Med: 36.69 Max: 211.57
Current: 15.79

During the past 13 years, Ono Pharmaceutical Co's highest Cash to Debt Ratio was 211.57. The lowest was 6.11. And the median was 36.69.

OPHLY's Cash-to-Debt is ranked better than
79.77% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs OPHLY: 15.79

Ono Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Ono Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ono Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

32.49

12.01

11.60

13.29

17.92

Ono Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																19.89	17.92	13.72	15.73	15.79

Competitive Comparison

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ono Pharmaceutical Co Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's Cash-to-Debt falls into.

Ono Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ono Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1229.117	/	(18.629	+	49.961)
	=	17.92

Ono Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	941.482	/	(15.738	+	43.895)
	=	15.79

Ono Pharmaceutical Co (OTCPK:OPHLY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ono Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OPHLF:USA 4528:Japan ON4:Germany

Address

8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564

Website

http://www.ono.co.jp

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines

From GuruFocus

Ono Pharmaceutical Co Stock Appears To Be Modestly Undervalued

By GF Value • 07-05-2021

T. Rowe Price Japan Fund Purchases 5 Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-18-2017

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

By PRNewswire • 12-01-2023

Samuel Isaly's Eaton Vance Worldwide Health Sciences Fund Q1 Investment Report

By Holly LaFon Holly LaFon • 05-13-2016